Cephalon Mustn't Talk IP At Pay-For-Delay Trial, FTC Says

The Federal Trade Commission asked a Pennsylvania federal judge Friday to bar Cephalon Inc. from discussing the validity of its patent for narcolepsy drug Provigil at trial, pointing to a recent...

Already a subscriber? Click here to view full article